GPCR — Structure Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $1.36bn
- $477.80m
- 44
- 34
- 13
- 20
Annual income statement for Structure Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 15.9 | 37.7 | 52.6 | 103 | 158 |
| Operating Profit | -15.9 | -37.7 | -52.6 | -103 | -158 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -15.7 | -37.8 | -51.3 | -89.4 | -122 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -15.9 | -38 | -51.3 | -89.6 | -123 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -15.9 | -38 | -51.3 | -89.6 | -123 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -16 | -43.8 | -52.8 | -89.6 | -123 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.146 | -0.399 | -0.481 | -0.813 | -0.776 |